BioNTech, DualityBio Say DYNASTY-Breast02 Phase 3 Trial Met Primary Endpoint, Showing Statistically Significant Yet Modest PFS Improvement For Trastuzumab Pamirtecan; Higher ILD Rate, OS Data Not Mature, Benefit Limited

Loading news article.

BioNTech, DualityBio Say DYNASTY-Breast02 Phase 3 Trial Met Primary Endpoint, Showing Statistically Significant Yet Modest PFS Improvement For Trastuzumab Pamirtecan; Higher ILD Rate, OS Data Not Mature, Benefit Limited | WAPE

BioNTech, DualityBio Say DYNASTY-Breast02 Phase 3 Trial Met Primary Endpoint, Showing Statistically Significant Yet Modest PFS Improvement For Trastuzumab Pamirtecan; Higher ILD Rate, OS Data Not Mature, Benefit Limited

Article summary

Related companies

Comments —